IE913732A1 - Oxindole peptide antagonists - Google Patents

Oxindole peptide antagonists

Info

Publication number
IE913732A1
IE913732A1 IE373291A IE373291A IE913732A1 IE 913732 A1 IE913732 A1 IE 913732A1 IE 373291 A IE373291 A IE 373291A IE 373291 A IE373291 A IE 373291A IE 913732 A1 IE913732 A1 IE 913732A1
Authority
IE
Ireland
Prior art keywords
methyl
formula
compound
compound according
butyl
Prior art date
Application number
IE373291A
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of IE913732A1 publication Critical patent/IE913732A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Indole Compounds (AREA)

Abstract

Oxindole peptide antagonists have formula (I), wherein R2 is =CH-Ar or spirohydantoin, and R1, R3 and R4 are as defined herein. The compounds of formula (I) are of use in the treatment of small cell mammalian cancers.

Description

This invention relates to novel oxindole derivatives, pharmaceutical compositions containing them, and methods of administering them to a subject in need of receptor binding inhibition of gastrin releasing peptide.
Gastrin releasing peptide (GRP) is known to stimulate a wide variety of biological responses in different tissues and cell lines including mitogenesis. GRP also plays a central role in the pathophysiology of small cell lung cancer. GRP inhibitors thus have clinical utility as inhibitors of pathophysiological response to GRP in human diseases. Prior art receptor binding GRP inhibitors are peptides such as disclosed in D.C. Heimbrook et al., Peptides, Proceedings of the Eleventh American Peptide Symposium, pages 56 to 59 (1989).
The present invention provides oxindoles which are receptor binding GRP inhibitors. Oxindoles have been described in U.S. Patents 4,464,380 and 4,644,005, both of which are incorporated herein by reference, as aldose reductase inhibitors. The present oxindoles and/or their activity as receptor binding inhibition of GRP are not disclosed.
In accordance with this invention, it has been found that certain novel oxindoles are active receptor binding inhibitors of GRP. These oxindoles have the general formula Ri wherein R, is methyl, ethyl, or benzyl which is phenyl40 substituted by one or two of chloro or bromo; R2 is =CH-Ar or spirohydantoin; R3 is alkyl, fluoro, chloro, bromo, iodo -2or R,; R^ is hydrogen, or one 5- or 6-substituent as follows: -O (CH2) bCONH2, -O(CH2)bOH, -O(CH2)bCO2H, -OCH2CH(OH)CH2OH, or benzyloxy which is phenyl-substituted by ortho or meta carboxy, hydroxymethyl or carbamoyl; or R, is two substituents: one 5-substituent as defined above and 6-methyl; n is 0, 1, 2, 3 or 4; Ar is imidazolyl, thienyl, pyrrolyl, piperazinyl, naphthyl, or wherein Rs is one of trif luoromethyl; or two of methyl, t-butyl or hydroxy; or one of methyl with one of hydroxy; or 3,5-di(t-butyl)-4-hydroxy; with the proviso that (1) R3 and R, are not both hydrogen, (2) R, is methyl or ethyl when R2 is =CH-Ar, and (3) R} is bromo or chloro and R, is 3,4-dichlorobenzyl when R2 is spirohydantoin.
Specific oxindoles of formula I are those wherein Rj is methyl or ethyl, and those wherein R2 is = CH-Ar in which Ar is 3,5-di(t-butyl)-4-hydroxybenzyloxy.
Other specific compounds of formula I are those wherein R3 is methyl, those wherein R3 is methyl and R* is -carbamoyl, 5-OCH2CONH2, or 5-carboxybenzyloxy, and those wherein R3 is methyl and R, is 5-carbamoyl-6-methyl, 5-OCH2CONH2, or 5-carboxybenzyloxy-6-methyl.
A preferred class of compounds of formula I is the class wherein R, is 3,4-dichlorophenyl and R2 is spirohydantoin.
The invention is further concerned with a pharmaceutical composition having receptor binding inhibitory activity toward GRP and comprising a compound of formula I in an amount sufficient to cause receptor binding inhibition of GRP, and a pharmaceutical carrier or diluent.
The invention also resides in a method for the receptor binding inhibition of gastrin releasing peptide by administering to a subject in need of receptor binding inhibition of gastrin releasing peptide a compound of the -3formula I as defined above in an amount sufficient to cause said inhibition.
The invention also resides in a method for the receptor inhibition of gastrin releasing peptide by administering to a subject in need of receptor binding inhibition of gastrin releasing peptide a compound of the formula wherein R, is methyl, ethyl, or benzyl which is optionally phenyl-substituted by one or two of chloro or bromo; and Rg is bromo or chloro, in an amount sufficient to cause said inhibition.
The oxindole compounds of the invention are made by different processes depending on whether Rj is =CH-Ar or spirohydantoin, and on whether the indole ring is 4-alkyl or 4-halo substituted.
The preparation of the oxindole compounds wherein R2 is spirohydantoin is described in above-mentioned U.S. Patent 4,464,380. According to this method, a compound of the formula is condensed with an alkali metal cyanide such as sodium cyanide or potassium cyanide, to form the corresponding spirohydantoin oxindole wherein R3 is chloro or bromo, and R* is as defined in connection with formula I. This -4condensation is generally carried out in the presence of a reaction-inert polar organic solvent in which both the reactants and the reagents are miscible. Preferred polar organic solvents include cyclic ethers such as dioxane and tetrahydrofuran, lower alkylene glycols such as ethylene glycol and trimethylene glycol, water-miscible lower alkanols such as methanol, ethanol and isopropanol, and N,N-di(Cj-C4 lower alkyl) Ct-C4 lower alkanoamides such as N, N-dimethylacetamide and Ν,Ν-dimethylacetamide. The reaction is generally conducted at a temperature of from about 50 to about 150°C for a period of time of about two hours to four days. Although the amount of reactant and reagents used may vary, it is preferable to use a slight molar excess of the alkali metal cyanide reagent with respect to the carbonyl ring starting material of formula II to obtain maximum yield.
The compounds of formula I wherein R2 is =CHAr may be prepared as depicted in Reaction Scheme I. R,, R3, R< and Ar in formulae III and IV of the Scheme are as defined above in connection with formula I.
The reaction of the oxindoles of formula III with the aldehydes of formula IV is generally conducted in a reaction-inert solvent. Suitable solvents include aromatic amines such as pyrrolidone or pyridine, aliphatic amines such as tetrahydrofuran, and alcohols such as methanol, ethanol, propanol and t-butanol. In a preferred method, the reaction solvent is methanol and pyrrolidine. The reaction is in general conducted at temperatures of from about -10°C to about 80°C. A preferred reaction temperature is room temperature.
The oxindole of formula III is advantageously first dissolved in a reaction-inert polar solvent such as a C,-C6 lower alkanol, e.g. methanol, before being combined with the aldehyde of formula IV.
The reaction of compounds III with compounds IV is conducted in the presence of a base. Suitable bases are alkali metal hydroxides such as sodium hydroxide, and -5organic bases such as pyrrolidine and pyridine. A preferred base is pyrrolidine.
Alternatively, the compounds of formula I wherein Rj is =CHAr may be prepared as depicted in Scheme II. R,, R3 and Ar in the formulae IV, V and VI of the Scheme are as defined above with reference to compounds of formula I. Rj in formula VII is (CH2)BCONH2, (CH2)BOH, (CH2).CO2H, CH2CH (OH) CH2OH, or benzyl substituted by ortho or meta carboxy, hydroxymethyl or carbamoyl. X in formula VII is halide such as chloride.
The reaction of the N-R,-hydroxy-indoles of the formula V with the aldehyde of formula IV proceeds as described above with reference to Reaction Scheme I.
The reaction of compounds VI with compounds VII 15 proceeds in the presence of a catalyst. Suitable catalysts are lithium bis(trimethylsilyl)amide, lithium bis(dimethylphenylsilyl) amide, lithium t-butyl (tri (C,-C6) alkylsilyl) amide and lithium hexamethyldisilylamide. A preferred catalyst is lithium bis(trimethylsilyl)amide. The reaction temperature ranges in general from about -78°C to about 10°C. A preferred reaction temperature range is from about -40 to -30°C. The reaction generally proceeds in the presence of a reaction-inert solvent. Suitable solvents are dimethylformamide, dimethylacetamide, tetrahydrofuran25 ethyleneglycoldimethyl ether. The preferred solvents are dimethylformamide and dimethylacetamide. -6Reaction Scheme I IV VI VII The starting material of formula V may be prepared by known methods. For instance, N-methyl-N-chloroacetylp-anisidine may be reacted with aluminum trichloride to form N-methyl-5-hydroxyoxindole.
The starting material of formula III may be prepared from the hydroxyindoles of formula V by reaction with compounds of formula VII as described above for the reaction of formula VI in Reaction Scheme II.
The compounds of formula VIII may be prepared as disclosed in U.S. Patent 4,464,380.
The novel compounds of formula I and the compounds of formula VIII are useful in the treatment of human diseases -7resulting from pathophysiological responses to GRP, e.g. the treatment of small cell lung cancer, the treatment of central nervous system disorders such as psychosis, panic disorders and mania, the treatment of gastrointestinal diseases such as gastric ulcers, and the treatment of eating disorders such as anorexia and bulimia.
The compounds of the invention may be administered alone, but will generally be administered in admixture with a pharmaceutical carrier selected with regard to the intended route of administration and standard pharmaceutical practice. For example, they can be administered orally or in the form of tablets containing such excipients as starch or lactose, or in capsules either alone or in admixture with excipients, or in the form of elixirs or suspensions containing flavoring or coloring agents. They can be injected parenterally, for example, intramuscularly, intravenously or subcutaneously. For parenteral administration, they are best used in the form of a sterile aqueous solution which can contain other solutes, for 0 example, enough salt or glucose to make the solution isotonic.
The invention also provides pharmaceutical compositions comprising an effective amount of a compound of the formula (I) together with a pharmaceutically acceptable diluent or carrier.
The compounds of the invention can be administered to humans for the treatment of diseases by either the oral or parenteral routes, and may be administered orally at dosage levels of about 0.1 to 500 mg/kg/day, advantageously 0.5-50 mg/kg/day given in a single dose or up to 3 divided doses. For intramuscular or intravenous administration, dosage levels are about 0.1-200 mg/kg/day, advantageously 0.5-50 mg/kg/day. While intramuscular administration may be a single dose or up to 3 divided doses, intravenous administration can include a continuous drip. Variations will necessarily occur depending on the weight and condition of the subject being treated and the particular route of -8administration chosen as will be known to those skilled in the art.
The activity of the present compounds in the receptor binding inhibition of GRP may be demonstrated by the following in vivo test. Small cell lung carcinoma derived cells are implanted subcutaneously into a thymic mice. These animals receive a test compound at specified time intervals to inhibit tumor growth. Non-treated mice succumb to the invading cells. In vitro activity of a test compound may be determined in an in vitro receptor binding assay using membranes of cells derived from small lung cell carcinoma.
The following examples illustrate the invention. Example 1 A. N-chloroacetvl-N-methvlanisidine To a solution of 5.98 ml of chloroacetylchloride in 68 ml of methylene dichloride under nitrogen at -10°C was dropwise added a mixture of N-methyl-anisidine (9.3 g) and diisoproylethylamine (14.2 ml) in 20 ml of methylene20 dichloride. The resulting mixture was allowed to warm up to room temperature and stirred at room temperature for 7 hours. Water (30 ml) was added and the organic layer was separated. Water (30 ml) was added again, and the mixture was acidified to pH 2 with hydrochloric acid, stirred for 15 minutes and extracted with methylene dichloride. The organic layer was separated, washed, dried and evaporated to give the title compound, 11.5 g(79%), m/e 213 (mass spec).
B. N-methvl-5-hydroxyindole To a 500 ml three neck flask containing 11.49 g of N-chloroacetyl-N-methyl-anisidine was added 15.78 g (0.118 mol, 2.2 mol equivalent) of A1C13 at room temperature under nitrogen. The mixture was stirred with a mechanical stirrer and gradually heated to 220°C. At 47°C a strong gas stream appeared. Fifteen minutes later, the mixture equilibrated at 221 °C and the stirring was continued at that temperature for two hours. After cooling to room temperature, ice water (200 ml) was added and the resulting mixture was stirred at -9room temperature overnight. The reaction mixture was filtered and the cake washed with water. The wet cake was recrystallized from ethylacetate and dried to provide 590 mg of title product, m.p. 198-199°C (dec.). Mass spectrum m/e 163.
C. 1-Methyl-3-methylene-ί3Z. 4y-di-tertiarv-butvl-4/hydroxv1-5-hydroxy oxindole To a solution of l-methyl-5-hydroxy oxindole (2 g, 12 mmole) in 60 ml of methanol was added 1.02 ml (12 mmoles) of pyrrolidine followed by 2.86 g (12 mmoles) of 3,5-ditert-butyl-4-hydroxy-benzaldehyde, and the resulting mixture was stirred at room temperature overnight. Then the reaction mixture was poured into a mixture of 100 ml of ice-water and 200 ml of IN HC1. The solid formed was collected by filtration and dried to give the title compound of 3.5 g (78%), m.p. 136-140°C (dec.). Mass spec, m/e 379, NMR (DMSO) 8.5 and 9 ppm (2H of OH), 6.7-7.2 ppm (aromatic 5H) , 3.4 ppm (3H of CHj) and 1.5 ppm (18H of tert-butyl).
D. 1-Methyl-f 3-methylene-(3 ',5'-tert-butyl-4'20 hvdroxv- phenyl)-5-(2'-carbomethoxvbenzvloxv)indole.
The title compound of step C (1.2 g, 3.16 mmoles), was dissolved in 12.4 ml of dimethyl formamide and cooled to -40°C under nitrogen. Then lithium bis(trimethylsilyl) amide, (6.95 ml, 6.95 mmoles) was added and the mixture stirred at -40°C for five minutes. To the resulting mixture was dropwise added 1.08 g (3.79 mmoles) of 2-bromoethyl benzoic acid methyl ester. The cooling bath was then removed and the reaction mixture was stirred at room temperature overnight. The reaction mixture was poured into a mixture of 100 ml of water and 200 ml of IN HC1, then extracted into ethyl acetate. The organic layer was separated, washed with water and saturated NaCl aqueous solution, dried over anhydrous magnesium sulfate, filtered and evaporated to give the crude product, 1.6 g.
Purification via silica gel column chromatography gave the fractions eluted with chloroform 820 mg (49%), m.p. 159162°C (dec.). Mass spec, m/e 527, NMR (CDC13) 6.8-8.2 -1010 ppm (aromatic 9H) , 4.9 and 5.2 ppm(3H, OH and CH2) , 3.9 ppm(3H of OCOCHj) , 3.3 ppm(3H of N-CH3) and 1.4 ppm(9H of tert-butyl).
E. 1-Methyl-3-methyleneΓ 3 ' . 4 '-di-tert-butvl-4 'hydroxy-phenvil-5-(2'-carboxybenzvloxy)-indole.
The title compound of step D (400 mg, 0.76 mmole) was hydrolyzed by dissolving in 3.8 ml of tetrahydrofuran, adding 3.8 ml of methanol and then introducing 3.8 ml of 6N NaOH. The resulting mixture was stirred at room temperature overnight, and then poured into a mixture of 100 ml of water and 100 ml of IN HCl. The precipitates formed were collected by filtration, washed with water, and dried to give the desired compound, 350 mg (90%), m.p. 124-125°C. Mass spec, m/e 513. Analysis, calcd. for C32H35NO5; C=74.81, H=6.87, N=2.73; found 0=74.68, H=6.28, N=2.53.
Example 2 A. 1-Methy1-3-methylene-Γ 3 ' . 4 '-di-tert-butvl-4'hydroxyΊ-5-hvdroxy oxindole To a solution of l-methyl-5-hydroxy oxindole (2 g, 12 mmole) in 60 ml of methanol was added 1.02 ml (12 mmoles) of pyrrolidine, followed by 2.86 g (12 mmoles) of 3,5-ditert-butyl-4-hydroxy-benzaldehyde. The resulting mixture was stirred at room temperature overnight. Then the reaction mixture was poured into a mixture of 100 ml of ice-water and 200 ml of IN HCl. The solid formed was collected by filtration and dried to give the title compound: 3.5 g (78%), m.p. 136-140°C (dec.). Mass spec, m/e 379. NMR (DMSO):8.5 and 9 ppm (2H of OH), 6.7-7.2 ppm (aromatic 5H) , 3.4 ppm (3H of CH3) and 1.5 ppm (18H of tert-butyl).
B. 1-Methyl-f3-methvlene-(3z.5'-tert-butyl-4'hydroxy-phenvl)-5-(2zcarbomethoxybenzvloxv)indole.
The compound of step A (1.2 g, 3.16 mmoles) was dissolved in 12.4 ml of dimethyl formamide and cooled to -40°C under nitrogen. Then lithium bis(trimethylsilyl) amide (6.95 ml, 6.95 mmoles) was added and the mixture was stirred at -40°C for five minutes. To the resulting mixture -11was added dropwise 1.08 g (3.79 mmoles) of 2-bromoethyl benzoic acid methyl ester. After the addition, the cooling bath was removed and the reaction mixture was stirred at room temperature overnight. The reaction mixture was poured into a mixture of 100 ml of water and 200 ml of IN HCl and extracted into ethyl acetate. The organic layer was separated, washed with water and saturated NaCl aqueous solution, and dried over anhydrous magnesium sulfate, filtered and evaporated to give the crude product, 1.6 g.
Purification via silica gel column chromatography gave the fractions eluted with chloroform, 820 mg (49%) , m.p. 159-162°C (dec.). Mass spec, m/e 527. NMR (CDC13) : 6.8-8.2 ppm (aromatic 9H) , 4.9 and 5.2 ppm (3H, OH and CH2) , 3.9 ppm (3H of OCOCH3) , 3.3 ppm (3H of N-CH3) and 1.4 ppm (9H of tert-butyl).
C. 1-Me thy1-3-methyleneΓ 3 ' . 4 '-di-tert-butyl-4 · hydroxy-phenyl 1 — 5 — f 2z carboxvbenzvloxv) -indole.
The benzoyloxy ester of step B (400 mg, 0.76 mmole) was hydrolyzed by dissolution in 3.8 ml of tetrahydrofuran and addition of 3.8 ml of methanol. Then, 3.8 ml of 6N NaOH was introduced. The resulting mixture was stirred at room temperature overnight and then poured into a mixture of 100 ml of water and 100 ml of IN HCl. Precipitate formed was collected by filtration, washed with water and dried to give the desired compound, 350 mg (90%), m.p. 124-125°C. Mass spec, m/e 513. Analysis, calcd. for C32H3SNO5: C=74.81, H=6.87, N=2.73; found C=74.68, H=6.28, N=2.53.
Example 3 According to the process of Example 2, the following compounds of formula I are prepared.

Claims (13)

  1. A compound of the formula PC7860AGXH . . .1 wherein R, is methyl, ethyl, or benzyl which is phenylsubstituted by one or two of chloro or bromo; R 2 is =CH-Ar or spirohydantoin; R 3 is C!-C 4 alkyl, fluoro, chloro, bromo, iodo or R 4 ; R 4 is hydrogen, or one 5- or 6-substituent as follows -O(CH 2 ) n CONH 2 , -O(CH 2 )„OH, -O (CH 2 ) a CO 2 H, -OCH 2 CH (OH) CH 2 OH, or benzyloxy which is phenyl-substituted by ortho or meta carboxy, hydroxymethyl or carbamoyl; or 20 R4 is two substituents: one 5-substituent as defined above and 6-methyl; n is 0, 1,
  2. 2. , 3 or 4; Ar is imidazolyl, thienyl, pyrrolyl, piperazinyl, naphthyl, or wherein R 5 is one of trifluoromethyl; or two of methyl, t-butyl 3 0 or hydroxy; or one of methyl with one of hydroxy; or
  3. 3. ,5-di(t-butyl)-4-hydroxy; with the proviso that (1) R 3 and R 4 are not both hydrogen, (2) R, is methyl or ethyl when R 2 is =CH-Ar, and (3) R 3 is bromo or chloro and Rj is 3,4-dichlorobenzyl when R 2 is spirohydantoin. 3 5 2. A compound according to claim 1 wherein R t is methyl or ethyl. -153 . A compound according to claim 1 or 2 wherein R 2 is =CH-Ar in which Ar is 3, 5-di(t-butyl)-4-hydroxybenzyloxy.
  4. 4. A compound according to anyone of claims l to 3 wherein R 3 is methyl.
  5. 5. A compound according to anyone of claims 1 to 4 wherein R 4 is 5-carbamoyl, 5-OCH 2 CONH 2 , or 5-carboxybenzyloxy.
  6. 6. A compound according to claim 5 wherein R, is 5-carbamoyl-6-methyl, 5-OCH 2 CONH 2 -6-methyl, or 5-carboxybenzyloxy-6-methyl.
  7. 7. A compound according to claim 1 wherein R t is 3,4-dichlorophenyl, and R 2 is spirohydantoin.
  8. 8. A pharmaceutical composition comprising a compound of the formula I as defined in claim 1, and a pharmaceutical carrier or diluent.
  9. 9. A compound of the formula I given and defined in claim 1, which is specifically hereinbefore mentioned.
  10. 10. A process for the preparation of a compound of the formula I given and defined in claim 1, substantially as hereinbefore described and exemplified.
  11. 11. A compound of the formula I given and defined in claim 1, whenever prepared by a process claimed in claim 10.
  12. 12. A pharmaceutical composition according to claim 8, substantially as hereinbefore described.
  13. 13. A compound according to any one of claims 1-7, 9 or 11 for use in therapy.
IE373291A 1990-10-29 1991-10-25 Oxindole peptide antagonists IE913732A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US60522090A 1990-10-29 1990-10-29

Publications (1)

Publication Number Publication Date
IE913732A1 true IE913732A1 (en) 1992-05-22

Family

ID=24422724

Family Applications (1)

Application Number Title Priority Date Filing Date
IE373291A IE913732A1 (en) 1990-10-29 1991-10-25 Oxindole peptide antagonists

Country Status (3)

Country Link
IE (1) IE913732A1 (en)
PT (1) PT99350A (en)
WO (1) WO1992007830A2 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2694004B1 (en) * 1992-07-21 1994-08-26 Adir News 3- (Hydroxybenzylidenyl) -indoline-2-ones and 3- (hydroxybenzylidenyl) -indoline-2-thiones, methods of preparation, and pharmaceutical compositions containing them.
TW281669B (en) * 1993-02-17 1996-07-21 Chugai Pharmaceutical Co Ltd
GB9313638D0 (en) * 1993-07-01 1993-08-18 Erba Carlo Spa Arylidene and heteroarylidene oxindole derivatives and process for their preparation
US5502072A (en) * 1993-11-26 1996-03-26 Pfizer Inc. Substituted oxindoles
US6316635B1 (en) 1995-06-07 2001-11-13 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US6147106A (en) 1997-08-20 2000-11-14 Sugen, Inc. Indolinone combinatorial libraries and related products and methods for the treatment of disease
US6906093B2 (en) 1995-06-07 2005-06-14 Sugen, Inc. Indolinone combinatorial libraries and related products and methods for the treatment of disease
RU2145852C1 (en) * 1996-01-17 2000-02-27 Тайхо Фармасьютикал Ко., Лтд Inhibitor of intima hypertrophy, use of hydroxyindole derivative for synthesis of inhibitor of intima hypertrophy, compositions for inhibition of intima hypertrophy, method of prophylaxis and treatment of intima hypertrophy
US6486185B1 (en) 1997-05-07 2002-11-26 Sugen, Inc. 3-heteroarylidene-2-indolinone protein kinase inhibitors
US6316429B1 (en) 1997-05-07 2001-11-13 Sugen, Inc. Bicyclic protein kinase inhibitors
US6531502B1 (en) 1998-01-21 2003-03-11 Sugen, Inc. 3-Methylidenyl-2-indolinone modulators of protein kinase
WO1999048868A2 (en) * 1998-03-26 1999-09-30 Sugen, Inc. Heterocyclic classes of compounds for the modulating tyrosine protein kinase
US6514981B1 (en) 1998-04-02 2003-02-04 Sugen, Inc. Methods of modulating tyrosine protein kinase function with indolinone compounds
US6569868B2 (en) 1998-04-16 2003-05-27 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
CO5031249A1 (en) 1998-05-29 2001-04-27 Sugen Inc PIRROL SUBSTITUTE-2-PROTEINCI-NASAS INHIBITING INDOLINONES
JP2002532503A (en) 1998-12-17 2002-10-02 エフ．ホフマン−ラ ロシュ アーゲー 4,5-Pyrazinooxindole as a protein kinase inhibitor
US6153634A (en) * 1998-12-17 2000-11-28 Hoffmann-La Roche Inc. 4,5-azolo-oxindoles
CN1138773C (en) * 1998-12-17 2004-02-18 霍夫曼-拉罗奇有限公司 4-alkenyl (and alkynyl) oxindoles as inhibitors of cell cycle protein dependent kinases, in particular CDK2
KR20010101266A (en) 1998-12-17 2001-11-14 프리돌린 클라우스너, 롤란드 비. 보레르 4-aryloxindoles as inhibitors of jnk protein kinases
US6689806B1 (en) 1999-03-24 2004-02-10 Sugen, Inc. Indolinone compounds as kinase inhibitors
US6878733B1 (en) 1999-11-24 2005-04-12 Sugen, Inc. Formulations for pharmaceutical agents ionizable as free acids or free bases
US6313310B1 (en) 1999-12-15 2001-11-06 Hoffmann-La Roche Inc. 4-and 5-alkynyloxindoles and 4-and 5-alkenyloxindoles
TWI270545B (en) 2000-05-24 2007-01-11 Sugen Inc Mannich base prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
EP1294688A2 (en) 2000-06-02 2003-03-26 Sugen, Inc. Indolinone derivatives as protein kinase/phosphatase inhibitors
US6504034B2 (en) 2001-01-23 2003-01-07 Hoffmann-La Roche Inc. Naphthostyrils
AR036042A1 (en) 2001-05-30 2004-08-04 Sugen Inc DERIVATIVES ARALQUILSUFONIL-3- (PIRROL-2-ILMETILIDEN) -2-INDOLINONA, ITS PHARMACEUTICAL COMPOSITIONS AND METHOD FOR THE MODULATION OF THE CATALYTIC ACTIVITY OF A KINASE PROTEIN
US20070021366A1 (en) * 2004-11-19 2007-01-25 Srivastava Satish K Structural-based inhibitors of the glutathione binding site in aldose reductase, methods of screening therefor and methods of use
US7795385B2 (en) * 2004-12-17 2010-09-14 Bexar Global, Inc. Use of bombesin/gastrin-releasing peptide antagonists for the treatment of inflammatory conditions, acute lung injury and bipolar disorder
EP1872795A4 (en) 2005-04-21 2009-07-22 Astellas Pharma Inc Therapeutic agent for irritable bowel syndrome
TW200801011A (en) 2006-02-07 2008-01-01 Astrazeneca Ab New compounds II
CN103274988B (en) * 2013-06-20 2016-04-13 河北大学 3-(cyano group-p-nitrobenzoyl support group)-2-indolone derivatives and preparation method and use thereof
CN115403566B (en) * 2022-09-21 2024-01-30 山东大学 3-substituted indol-2-one compound, preparation method and application thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU532110B2 (en) * 1979-11-13 1983-09-15 Ici Ltd. Spiro(imidazolidine-4,3:-indoline)-2,2:5-trione derivatives
US4971996A (en) * 1987-03-11 1990-11-20 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Hydroxystyrene compounds which are useful as tyrosine kinase inhibitors

Also Published As

Publication number Publication date
WO1992007830A2 (en) 1992-05-14
PT99350A (en) 1992-10-30
WO1992007830A3 (en) 1992-06-25

Similar Documents

Publication Publication Date Title
IE913732A1 (en) Oxindole peptide antagonists
JP5680469B2 (en) Synthesis of amines and intermediates for their synthesis
JPH10503501A (en) Indole, indazole, pyridopyrrole and pyridopyrazole derivatives having anti-asthma, anti-allergy, anti-inflammatory and immunomodulatory effects
JPH093063A (en) Piperidinylmethyl-substituted indole derivative
AU716435B2 (en) Novel indole-2,3-dione-3-oxime derivatives
KR20050099525A (en) Process for preparing pyrrolotriazine kinase inhibitors
JPS63135382A (en) Imidazepyridines production thereof and application thereof to drug
CH633796A5 (en) THERAPEUTICALLY ACTIVE DIPYRIDOINDOLES.
JP2002509930A (en) Benzoheterocyclic distamycin derivatives, process for their preparation and their use as antitumor agents
CZ323794A3 (en) N-substituted azabicycloheptane derivatives, process of their preparation and their use
IE891169L (en) Cyclic amides
HU190573B (en) Process for producing new beta-carboline derivatives and pharmaceutical compositions cintaining them
SK7595A3 (en) Tetracyclic compounds process and intermediates for their preparation and their use as antitumour agents
CA3075324A1 (en) Deuterium atom-substituted indole formamide derivative, preparation method therefor, and medical applications thereof
JP3465827B2 (en) Azaindole derivative and anti-ulcer drug containing the same as active ingredient
JP3242652B2 (en) Pyrroloazepine derivatives
US4053600A (en) Tricyclic 1,2,4-triazolo-quinazolines
US4268513A (en) Pyrrolo [3,4-c]quinoline compounds and pharmaceutical compositions, methods for their use and preparation
US4440768A (en) Hexahydropyrrolo[3,4-c]quinoline compounds and pharmaceutical compositions, and methods for their use
ES2247107T3 (en) NEW POLYCLY INDANILIMIDAZOLS WITH ADRENERGIC ACTIVITY.
US3957785A (en) Bβ-Pyrimidino-aminomethyl-10α-ergoline and 10α-methoxyergoline derivatives
US20090124682A1 (en) Indan-Amide Derivatives with Glycogen Phosphorylase Inhibitory Activity
EP0402232A1 (en) Pyridobenzoindole derivatives, their preparation and compositions containing them
US6458792B1 (en) Compounds
US4350814A (en) Pyrrolo [3,4-c]quinoline compounds